



## **ENTOD Pharmaceuticals Introduces a Saffron based Eye Care Product in India to Promote Visual Performance**

**January, 2022:** ENTOD Pharmaceuticals, a research-based pharmaceutical organisation with over four decades of pharmaceutical expertise in Ophthalmology, ENT and Dermatology medicine has come up with a **saffron-based eye care supplement, MACUSAFF™ capsule in India. Manufactured from 100 per cent DNA certified Persian origin natural saffron extract with guaranteed 5% crocins and specially imported from France.** This natural eye supplement helps with various eye conditions like age-related macular degeneration, glaucoma, diabetic retinopathy and retinitis pigmentosa.

Presently, there's a lot of buzz around saffron and its ability to support optimal eye health. The benefits of saffron for the eyes are the result of high concentrations of natural carotenoids that can help protect the retina and the lens of aging eyes. **Saffron helps restore the structure and function of retinal cells.**

Speaking about the launch of the new product, **Mr Nikkhil K Masurkar, Executive Director of ENTOD Pharmaceuticals** said "Saffron is a spice, which is harvested from the fall-flowering plant *Crocus Sativus*, a member of the Iris family, and commonly known as saffron. **Saffron is a spice that contains the antioxidant carotenoids crocin and crocetin among other ingredients, with strong antioxidative, cellular and neuroprotective properties.** Based on animal and in-vitro research, modern medicine has discovered that saffron has anticarcinogenic, immunomodulating, neuroprotective, eye health and antioxidant-like properties. Saffron contains carotenoids crocin and crocetin that have shown strong protective effects on retinal cells that help restore the function and structure of retinal cells damaged by oxidative stress in age-related macular degeneration. **Our saffron-based MACUSAFF™ veg capsule improves retinal flicker sensitivity, blood flow, protects RGC, reduce intraocular pressure and supports natural mechanisms of the eye."**

A clinical study has shown that taking oral supplementation of **saffron (20 mg per day) for 3 months in patients with early-stage age-related macular degeneration (AMD or ARMD) induced a significant improvement of retinal function and visual clarity.** Saffron has some unique properties for modifying the activity level of specific genes in the retina of the eye that play an important role in the protection and repair of retinal cells. The beneficial effects of supplementation with saffron in early age-related macular degeneration are unique and have not been observed with other nutrients.

"Apart from AMD, saffron extract decreases the intraocular pressure in patients with primary ocular angle glaucoma a pilot study revealed. Other than that, antioxidant carotenoid crocin present in saffron decreases the central macular thickness and improves the best-corrected visual acuity in patients suffering from diabetic retinopathy, studies have revealed. Also, saffron has remarkable effects on the genes which regulate the performance of the eye's key vision cells and not only protects the vision cells (photoreceptors) from damage but may also slow and possibly even reverse the course of blinding





# Entod Pharmaceuticals Ltd

Quality, Innovation & Research Since 1977

ISO 9001:2015 & ISO 13485:2016 Certified

Ophthalmology | ENT | Paediatrics | Dermatology

diseases such as age-related macular degeneration (AMD) and retinitis pigmentosa. **MACUSAFF™** offers a full spectrum of eye health ingredients at sensible levels in a convenient once-daily capsule” said **Mrs. Anjula Masurkar, Clinical Director of ENTOD Pharmaceuticals.**

The DNA tested, gluten-free capsule is more than a mere antioxidant. Crocin, a unique substance found in saffron that has been proven to improve the way genes work together to repair and maintain cells in the retina of the eye.

#### **Disclaimer:**

*Statements in this “Document” describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.*

#### **About ENTOD Pharmaceuticals Limited (CIN - U24230MH1981PLC025529):**

ENTOD Pharmaceuticals is an international research-based pharmaceutical organisation with over three decades of pharmaceutical expertise in Ophthalmology, ENT, Dermatology & other speciality medicine. Globally we have over 200 products in our portfolio, a global field force of over 1000 and highly experienced Quality Assurance, Production and R&D teams. Our products are sold in over 55 countries including the EU, UK, Africa and Asia. Our quality systems are certified in Europe and our manufacturing quality standards adheres to international GMP norms. Our product range includes intracameral injections, eye drops, eye ointments, eye gels and soft gelatin capsules

For further information, please visit [www.entodpharma.com](http://www.entodpharma.com) & follow us on Twitter@EntodPharma

